Press release
Signature Diagnostics announces a Clinical Research Collaboration with OncoMethylome Sciences
Potsdam, Germany - September 13, 2006.Signature Diagnostics announces today that it has entered into a Clinical Research Collaboration in the field of colorectal cancer (CRC) with OncoMethylome Sciences to make available its clinical CRC platform for the development and validation of new molecular diagnostics. OncoMethylome Sciences is a public diagnostic company with offices in Liege, Leuven (Belgium), Amsterdam (the Netherlands) and Durham (NC; USA).
Starting immediately Signature Diagnostics will provide OncoMethylome Sciences with prospective tissue samples including tumor samples, plasma and stool samples as well as associated clinical data from CRC patients from all four stages of the disease.
Prof. André Rosenthal, Chief Executive Officer of Signature Diagnostics, states: «We are pleased that OncoMethylome Sciences has recognized the value of our clinical technology platform and our capability to run large multi-center prospective diagnostic trials within Germany. I am convinced that our collaboration will accelerate the validation and development of novel diagnostic products both at OncoMethylome Sciences and Signature Diagnostics. Prospective tissue sample collections are an essential component of the development of novel genomics-based diagnostics and we are excited to be able to collaborate with OncoMethylome Sciences in this strategic field.”
Financial figures are not disclosed.
For further information, please contact:
Prof. Dr. André Rosenthal, CEO
Signature Diagnostics AG
Voltaireweg 4B
D-14469 Potsdam
Germany
Phone: +49-331-6207575
email: andre.rosenthal@signature-diagnostics.de
Signature Diagnostics AG (www.signature-diagnostics.de) is a molecular diagnostic company dedicated to the discovery, validation and commercial development of novel diagnostic products that predict outcome and drug response in patients with colorectal cancer. Signature believes that patient selection and stratification based on gene signatures will soon become an important component of routine cancer treatment. Signature improves the quality of decision making in cancer treatment and patient care.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Signature Diagnostics announces a Clinical Research Collaboration with OncoMethylome Sciences here
News-ID: 11221 • Views: …
More Releases for OncoMethylome
Visiongain Launches New Report: Epigenetics Diagnostic Report 2019-2029
Epigenetics Diagnostic Report 2019-2029: Analysis by Product (Reagents, Kits, Instruments, Enzymes, Services), by Technology (DNA Methylation, Histone Methylation, Histone Acetylation, Large Non-coding RNA, MicroRNA Modification, Chromatin Structures), by Application (Oncology, Non-oncology) and by Region (North America, Europe, Asia Pacific, Latin America, MEA), Company and Country Analysis and Forecasts.
Market Definition:
-Epigenetics is referred to all molecular pathways modulating the expression of a genotype into a particular phenotype. Epigenetics consistently indicates…
Oncology Molecular Diagnostics Global Market by Cancer Type, Trends, Analysis an …
Molecular diagnostics is one of the most transformative and dynamic areas of diagnostics. It is a technique used for analyzing biological markers in proteome and genome. Molecular diagnostics tests are increasingly used in oncology, infectious disease, pharmacogenomics, and human leukocyte antigen typing.
Oncology molecular diagnostics is a major application of molecular biology and is increasingly used for cancer screening, therapy selection, diagnosis, and relapse monitoring. Some of the major that…
